



ELSEVIER

Contents lists available at ScienceDirect

Journal of Cardiology

journal homepage: [www.elsevier.com/locate/jjcc](http://www.elsevier.com/locate/jjcc)

Original article

## Risk of myocardial infarction in patients with psoriasis: A cross-sectional patient-population study in a Japanese hospital



Masayuki Shiba (MD)<sup>a</sup>, Takao Kato (MD, PhD)<sup>b,\*</sup>, Toshiaki Izumi (MD, PhD)<sup>c</sup>,  
Shoichi Miyamoto (MD, PhD)<sup>c</sup>, Eisaku Nakane (MD)<sup>c</sup>, Tetsuya Haruna (MD, PhD)<sup>c</sup>,  
Moriaki Inoko (MD, PhD)<sup>c</sup>

<sup>a</sup> Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan

<sup>b</sup> Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

<sup>c</sup> Cardiovascular Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

## ARTICLE INFO

## Article history:

Received 9 August 2018

Received in revised form 30 September 2018

Accepted 10 October 2018

Available online 21 December 2018

## Keywords:

Psoriasis

Myocardial infarction

Japan

## ABSTRACT

**Background:** Some epidemiological studies have demonstrated the association between psoriasis vulgaris and coronary artery disease (CAD). However, there is a lack of specific data regarding the association between psoriasis vulgaris and myocardial infarction (MI), the more severe and critical presentation of CAD, in the Japanese population.

**Methods and results:** We retrospectively analyzed 113,065 patients of all ages at our hospital from January 1, 2011 to January 1, 2013. We extracted the data of patients with psoriasis vulgaris, diabetes mellitus, dyslipidemia, or MI (acute, sub-acute, or old), including sex and age from the electronic medical record database. The prevalence of MI in patients with hypertension, dyslipidemia, diabetes mellitus, and psoriasis vulgaris were 4.8% (794/16,476), 5.0% (459/9236), 4.6% (531/11,555), and 2.7% (32/1197), respectively. Multivariate analysis showed that psoriasis vulgaris was significantly associated with MI [adjusted odds ratio (OR): 1.87; 95% confidence interval (CI): 1.26–2.68;  $p = 0.0022$ ]. In a subgroup analysis of 24,069 patients who had one or more comorbidities including diabetes mellitus, dyslipidemia, and hypertension, psoriasis vulgaris was still independently associated with MI after adjusting for sex and age (adjusted OR, 1.49; 95% CI: 1.02–2.18;  $p = 0.0358$ ) in adults.

**Conclusion:** Psoriasis vulgaris was significantly associated with MI in a Japanese hospital-based population.

© 2018 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.

## Introduction

Psoriasis vulgaris is regarded as an immune-mediated chronic low-level inflammatory skin disorder associated with metabolic and cardiovascular comorbidities [1–3]. Some epidemiological studies have shown that, although there was a racial difference in the prevalence of psoriasis [4–8], there was a clear association between psoriasis vulgaris and coronary artery disease (CAD) regardless of race [9–12], as we previously reported in a hospital-based Japanese population [13]. In addition, the association with the risk of myocardial infarction (MI), a

more severe and clinically significant condition of CAD, and psoriasis was reported in the USA, Europe, central China, and Taiwan [14–22]. However, there is a lack of data regarding the association between MI and psoriasis vulgaris in the Japanese population. In the present study, we tested the hypothesis that psoriasis vulgaris is independently associated with MI in a Japanese hospital-based population.

## Methods

## Patients and data collection

From the medical accounting system we retrospectively researched all clinic and in-hospital 113,065 patients of all ages from January 1, 2011 to January 1, 2013 in this cross-sectional observational study. First, we identified the total number of

\* Corresponding author at: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.

E-mail address: [tkato75@kuhp.kyoto-u.ac.jp](mailto:tkato75@kuhp.kyoto-u.ac.jp) (T. Kato).


patients from the medical accounting system. Second, we extracted the data of patients with psoriasis, metabolic comorbidities, or MI regarding sex, age, and diagnoses including psoriasis vulgaris [International Classification of Diseases (ICD)-10 code L40.0], hypertension (ICD-10 codes I10, I11, I12, I13, I14, and I15), dyslipidemia (ICD-10 code E78), diabetes mellitus (ICD-10 codes E10, E11, E12, E13, and E14), and acute, sub-acute, or old MI (ICD-10 codes I21, I22, and I25.2, respectively) from the medical record database. Hypertension, dyslipidemia, and diabetes mellitus are the typical risk factors for MI and regarded as potential confounders. If the diagnoses of each disease were recorded in the medical charts, we considered each disease as present. Patient data were automatically extracted from the medical accounting system. We evaluated the risk of MI in patients with psoriasis vulgaris. The present study was approved by the institutional review board of Kitano Hospital (P15-06-005) in concordance with the Declaration of Helsinki. Patient consent was not obtained because of the retrospective study. We disclosed the detail of the present study to the public as an opt-out method and the notice clearly informed patients of their right to refuse enrollment. Identifiable patient data were anonymized before analysis.

**Statistics**

A chi-square test was performed for categorical variables summarized as counts and percentages. The Wilcoxon rank sum test was used for continuous variables summarized as mean and standard deviation. To analyze the comorbid factors associated with MI, we used a multivariable logistic regression model that involved the following variables: psoriasis vulgaris, diabetes mellitus, dyslipidemia, and hypertension. In this first analysis, we did not include sex and age in the model because of the lack of data in the total population. Second, to analyze the association between psoriasis and MI in patients with one comorbidity or more including diabetes mellitus, dyslipidemia, and hypertension, we performed a sub-analysis with a multivariable logistic regression model that involved age, sex, psoriasis vulgaris, diabetes mellitus, dyslipidemia, and hypertension in adults (the age more than or equal to 20 years). In the subgroup analysis, we used risk-adjusting variables for excluding each subgrouping factor without adjustment for multiple tests. We also evaluated the interactions between the subgroup factors and the effect of psoriasis for the MI. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A two-tailed *p*-value less than 0.05 was considered statistically significant in all analyses. Statistical analyses were performed using JMP pro software, version 13 (SAS Corp., Cary, NC, USA).

**Results**

The comorbidities of this study population are shown in Table 1. Patients with psoriasis had a higher prevalence of



**Fig. 1.** Extraction of patients by international classification of diseases (ICD) – 10 codes.

hypertension, hyperlipidemia, diabetes mellitus, and MI. Fig. 1 indicates the comorbidities of patients with psoriasis and as the figure shows, MI was present in 966 (0.85%) patients. The prevalence of MI in patients with hypertension, dyslipidemia, diabetes mellitus, and psoriasis vulgaris was 4.8% (794/16,476), 5.0% (459/9236), 4.6% (531/11,555), and 2.7% (32/1197), respectively (Table 1).

By multivariate analysis, after adjusting for psoriasis vulgaris, diabetes mellitus, dyslipidemia, and hypertension, we established that psoriasis vulgaris was significantly associated with MI (adjusted OR: 1.87; 95% CI: 1.26–2.68; *p* = 0.0022), along with hypertension (adjusted OR: 14.57; 95% CI: 12.12–17.58; *p* < 0.0001), dyslipidemia (adjusted OR: 2.12; 95% CI: 1.84–2.44; *p* < 0.0001), and diabetes mellitus (adjusted OR: 2.46; 95% CI: 2.13–2.84; *p* < 0.0001) (Fig. 2).

In the second analysis of 23,916 adult patients who had one or more comorbidities including diabetes mellitus, dyslipidemia, and hypertension, psoriasis vulgaris was still independently associated with MI (adjusted OR, 1.49; 95% CI: 1.02–2.18; *p* = 0.0358, Table 2) after adjusting for diabetes mellitus, dyslipidemia, hypertension, sex, and age.

In subgroup analyses, there were no interactions between the subgrouping factors and the effect of psoriasis vulgaris on the presence of MI (Fig. 3).

**Discussion**

In the present study, we demonstrated the independent association between MI and psoriasis vulgaris in a Japanese patient-population.

Many patients with psoriasis vulgaris have overlapping risk factors for MI. In the present study, psoriasis was independently associated with MI in a cohort of 113,065 patients and in a sub-population of 24,069 patients with one and more comorbidities in

**Table 1**  
Baseline characteristics of patients with psoriasis.

Variables	With psoriasis				Without psoriasis			
	Total	MI		Total	MI			
		Present	Absent		Present	Absent		
Numbers	1197	32 (2.7%)	1165 (97.3%)	111,868	934 (0.8%)	110,934 (99.2%)		
Age (years, mean, SD)	64.1, 18.9	63.8, 18.9	75.7, 12.7	n/a	74.7, 11.3	n/a		
Male	762 (63.6%)	27 (84.3%)	735 (63.0%)	n/a	694 (74.3%)	n/a		
Hypertension	288 (24.0%)	31 (96.8%)	257 (22.0%)	16,188 (14.4%)	763 (1.6%)	15,425 (13.9%)		
Dyslipidemia	231 (19.2%)	22 (68.7%)	209 (17.9%)	9005 (8.0%)	437 (46.7%)	8568 (7.7%)		
Diabetes	252 (21.0%)	17 (53.1%)	235 (20.1%)	11,303 (10.1%)	514 (55.0%)	10,789 (9.7%)		

MI, myocardial infarction; SD, standard difference; n/a, not available.

Factors	Adjusted OR (95%CI)	p value
Hypertension	14.57 (12.12–17.58)	<0.0001
Dyslipidemia	2.12 (1.84–2.44)	<0.0001
Diabetes mellitus	2.46 (2.13–2.84)	<0.0001
Psoriasis	1.87 (1.26–2.68)	0.0022




Fig. 2. The independent association between psoriasis and myocardial infarction after adjusting for hypertension, dyslipidemia, and diabetes mellitus. OR, odds ratio; CI, confidence interval.

Table 2

Adjusted risk of myocardial infarction in adult patients who had one or more comorbidities including diabetes mellitus, dyslipidemia, and hypertension.

Factors	Adjusted OR (95% CI)	p-Value
Age (1-year increment)	1.03 (1.02–1.04)	<0.0001
Male	3.21 (2.73–3.77)	<0.0001
Hypertension	4.94 (3.89–6.27)	<0.0001
Dyslipidemia	1.98 (1.72–2.28)	<0.0001
Diabetes mellitus	1.79 (1.55–2.07)	<0.0001
Psoriasis	1.49 (1.02–2.18)	0.0358

OR, odds ratio; CI, confidence interval.

Japan. This result was consistent with research performed in Europe, North America, and Asia [14–22]. However, there were conflicting results in other published studies that did not show a significant relationship between psoriasis and MI [23–27]. In a large population-based Dutch cohort study, Wakkee et al. showed that the risk of MI was not significant in patients with psoriasis (HR: 0.94; 95% CI: 0.80–1.11) [25]. The presence or absence of arthritis is one reason why the discrepancies existed [28]. Chin et al. and Ogdie et al. reported that psoriasis patients with arthritis had a greater risk of cardiovascular comorbidities or MI than psoriasis patients without arthritis [29,30]. Other reasons for the conflicting results may be due to the severity and the duration of psoriasis. A recent study by Egeberg et al., which included 61,603 patients with psoriasis and 4,300,085 controls, revealed a significant association between MI and psoriasis only in patients with severe psoriasis (HR: 1.21, 95% CI: 1.07–1.37) [24]. Armstrong

et al. indicated that patients who had psoriasis for over an 8-year period had a greater prevalence of CAD [9]. However, the association between MI and psoriasis has been almost never studied in Japan. Future studies are necessary to research the general Japanese population and consider, age, sex, smoking, and psoriasis severity, duration, and treatment in order to show that psoriasis is truly an independent risk factor for myocardial infarction in the general Japanese population. In the present study, we could not assess the incidence of MI during the follow-up period due to the cross-sectional design. In addition, the severity of psoriasis was not mentioned in the data collected from the electrical medical records. However, after adjusting for available confounders, psoriasis was still independently associated with MI in a large Japanese population.

Psoriasis is a systemic inflammatory disease that mainly affects the skin. Inflammatory mediators produced by Type 1 helper T (Th1) and Type 17 helper T (Th17) cells cause systemic inflammation and vascular atherosclerosis [31–33]. Since the susceptibility to psoriasis may differ due to the genetic background [7,8] and the prevalence of psoriasis in Japan is not high [13,34], the attributable risk of psoriasis vulgaris for MI may be small in Asian countries. However, the patients with psoriasis vulgaris should be carefully managed for controlling the atherosclerotic risks, especially MI, the life-threatening disease condition, during clinical practice.

The present study has several limitations. First, the population in our study was not the general Japanese population, but a patient-population in a Japanese hospital. The prevalence of each disease in our study may be higher than that of the general Japanese population [34]. A nationwide study would be helpful to generalize the results in this study. Second, we could not collect data regarding smoking, blood tests, and body weight; in addition, information on age and sex was disease-specifically extracted. This lack of data might have resulted in insufficient adjustment. Third, diagnostic codes consistent with the diseases may have included only registered codes acceptable to the Japanese health care insurance system. The ICD diagnosis codes have not been validated. However, Kubota et al. surveyed demographic characteristics of psoriasis vulgaris using ICD-10 codes and they found the demographic findings were common to the whole population and dermatology/rheumatology department [34]. They suggested that all patients identified by the claims diagnosis codes in their study roughly represented all patients with psoriasis who used healthcare services. However, we did not have the data of codes from which department the codes were reported. Fourth, it was possible that serious diseases including MI might often accompany the intensive systemic physical examination that revealed the existence of psoriasis vulgaris. Fifth, the information regarding the severity and treatment of psoriasis vulgaris was not collected.




Fig. 3. Subgroup analysis. OR, odds ratio; CI, confidence interval.

Finally, the time course of each disease was not taken into account because of the cross-sectional design. Larger, longitudinal cohort studies could address the cause–effect relationship between psoriasis and MI.

## Conclusion

Psoriasis vulgaris was independently associated with the presence of MI within a patient-population in Japan.

## Funding

This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Conflict of interest

The authors declare that there is no conflict of interest.

## References

- [1] Libby P, Nahrendorf M, Swirski FK. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded “cardiovascular continuum”. *J Am Coll Cardiol* 2016;67:1091–103.
- [2] de Souza Bastos A, Graves DT, de Melo Loureiro AP, Júnior CR, Corbi SCT, Frizzera F, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. *J Diabetes Complications* 2016;30:1593–9.
- [3] Herder C, Færch K, Carstensen-Kirberg M, Lowe GD, Haapakoski R, Witte DR, et al. Biomarkers of subclinical inflammation and increases in glycaemia, insulin resistance and beta-cell function in non-diabetic individuals: the Whitehall II study. *Eur J Endocrinol* 2016;175:367–77.
- [4] Lee YH, Song GG. Vascular endothelial growth factor gene polymorphisms and psoriasis susceptibility: a meta-analysis. *Genet Mol Res* 2015;14:14396–405.
- [5] McMichael AJ, Vachiram V, Guzman-Sanchez DA, Camacho F. Psoriasis in African-Americans: a caregivers’ survey. *J Drugs Dermatol* 2012;11:478–82.
- [6] Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. *J Am Acad Dermatol* 2014;70:512–6.
- [7] Yin X, Low HQ, Wang L, Li Y, Ellinghaus E, Han J, et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. *Nat Commun* 2015;6:6916.
- [8] Kim J, Oh CH, Jeon J, Baek Y, Ahn J, Kim DJ, et al. Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets. *J Invest Dermatol* 2016;136:161–72.
- [9] Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ. Coronary artery disease in patients with psoriasis referred for coronary angiography. *Am J Cardiol* 2012;109:976–80.
- [10] Mahiques-Santos L, Soriano-Navarro CJ, Perez-Pastor G, Tomas-Cabedo G, Pitarch-Bort G, Valcuende-Cavero F. Psoriasis and ischemic coronary artery disease. *Actas Dermosifiliogr* 2015;106:112–6.
- [11] Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. *Br J Dermatol* 2007;156:271–6.
- [12] Dregan A, Charlton J, Chowieniczky P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. *Circulation* 2014;130:837–44.
- [13] Shiba M, Kato T, Funasako M, Nakane E, Miyamoto S, Izumi T, et al. Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan. *PLoS ONE* 2016;11:e0149316.
- [14] Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. *J Eur Acad Dermatol Venereol* 2009;23:1311–5.
- [15] Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. *J Am Acad Dermatol* 2011;64:495–501.
- [16] Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. *Br J Dermatol* 2008;159:895–902.
- [17] Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006;296:1735–41.
- [18] Wu JJ, Choi YM, Bechuk JD. Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. *J Dermatolog Treat* 2015;26:230–4.
- [19] Koch M, Baurecht H, Ried JS, Rodriguez E, Schlesinger S, Volks N, et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. *J Invest Dermatol* 2015;135:1283–93.
- [20] Lai YC, Yew YW. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. *J Cutan Med Surg* 2016;20:327–33.
- [21] Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in Canadian patients with psoriasis: a retrospective cohort study. *J Cutan Med Surg* 2013;17:398–403.
- [22] Ahlehoff O, Gislason GH, Charlott M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. *J Intern Med* 2011;270:147–57.
- [23] Maradit-Kremers H, Dierkhising RA, Crowson CS, Icen M, Ernste FC, McEvoy MT. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. *Int J Dermatol* 2013;52:32–40.
- [24] Egeberg A, Thyssen JP, Jensen P, Gislason GH, Skov L. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. *Acta Derm Venereol* 2017;97:819–24.
- [25] Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. *J Invest Dermatol* 2010;130:962–7.
- [26] Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. *J Eur Acad Dermatol Venereol* 2010;24:885–92.
- [27] Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case–control analysis. *Br J Dermatol* 2009;160:1048–56.
- [28] Ogdie A, Troxel AB, Mehta NN, Gelfand JM. Psoriasis and cardiovascular risk: strength in numbers. Part 3. *J Invest Dermatol* 2015;135:2148–50.
- [29] Chin YY, Yu HS, Li WC, Ko YC, Chen GS, Wu CS, et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. *J Eur Acad Dermatol Venereol* 2013;27:1262–8.
- [30] Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis* 2015;74:326–32.
- [31] Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients: current and future. *Am J Clin Dermatol* 2013;14:1–7.
- [32] Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. *Thromb Haemost* 2011;106:787–95.
- [33] Karbach S, Croxford AL, Oelze M, Schüler R, Minwegen D, Wegner J, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. *Arterioscler Thromb Vasc Biol* 2014;34:2658–68.
- [34] Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. *BMJ Open* 2015;5:e006450.